Institute Of Hematology & Blood Diseases Hospital, China

This study tests if thalidomide alone can help people with a rare blood cancer called large granular lymphocytic (LGL) leukemia. About 48 adults with symptoms will take thalidomide pills for up to 3 months. If it doesn't work well enough, another drug (methotrexate) may be added.…

This study tests a three-drug combination (ZGR) as the first treatment for people with mantle cell lymphoma who have not had any prior therapy. About 37 adults aged 18 to 80 will receive the drugs, and those at higher risk may also get CAR-T cell therapy followed by maintenance d…

This study compares a new drug called daratumumab with the standard drug rituximab in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The goal is to see which drug works better at raising platelet counts and redu…

This early-stage study tests a new treatment called universal CD7 CART cells for people with relapsed or hard-to-treat blood cancers that carry a specific marker (CD7). The therapy uses specially engineered immune cells from a donor to attack cancer cells. The main goals are to c…

This study tests a combination of two drugs (CM336 and isatuximab) in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function and control the myeloma. Participants receive three cycles…

This study tests a combination of radiation and a drug called CM336 (a bispecific antibody) in people with a rare bone tumor called solitary bone plasmacytoma that has mild bone marrow involvement. The goal is to see if this approach is safe and can keep the cancer from progressi…

This early-stage study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that cause autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment is given as a one-time infusion and aims…

This study is testing a three-drug combination (venetoclax, ivosidenib, and azacitidine) in adults with a specific genetic form of acute myeloid leukemia (AML) called IDH1-mutated. The goal is to see if this combination can improve remission rates and survival. About 23 participa…

This study tests whether a combination of two antifungal drugs (liposomal amphotericin B plus posaconazole or isavuconazole) can better treat a serious fungal infection called mucormycosis in adults with blood cancers like leukemia or lymphoma. About 60 participants will receive …

This study is for people newly diagnosed with a type of acute myeloid leukemia (AML) that has a specific genetic change called FLT3 mutation, which makes the disease harder to treat. The trial will test a combination of three drugs—gilteritinib, venetoclax, and azacitidine—to see…

This study is for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It tests a treatment plan that combines targeted drugs, reduced-intensity chemotherapy, and CAR-T cell therapy to deepen remission and reduce side effects. The g…

This study is for people aged 14 to 60 with a specific genetic type of acute myeloid leukemia (AML) called RUNX1-RUNX1T1. It compares two different doses of a chemotherapy drug (cytarabine) given with another drug (anthracycline) to see which works better at improving survival. T…

This early study tests if umbilical cord stem cells can safely help people whose blood cell counts stay low after CAR-T therapy. It includes 15 adults with leukemia, lymphoma, or myeloma. The goal is to see if the stem cells improve blood counts and reduce the need for transfusio…

This early study tests whether zoledronic acid, a drug usually used for bone health, can help people with a rare inherited blood disorder called congenital dyserythropoietic anemia (CDA). The goal is to see if it can raise hemoglobin levels and reduce the need for blood transfusi…

This study tests two different chemotherapy combinations in adults aged 55 to 75 with acute myeloid leukemia (AML) who are healthy enough for strong treatment. One group gets a newer drug combo (venetoclax plus azacitidine), while the other gets standard chemotherapy. The goal is…

This study tests a powerful treatment plan for people newly diagnosed with a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines standard chemotherapy drugs with two rounds of CAR T-cell therapy and a stem cell transplant. The goal is to se…

This study tests whether combining two drugs (rituximab and daratumumab) can safely raise platelet counts in adults with immune thrombocytopenia (ITP) who did not get better with steroids. About 20 participants will receive the combo and be monitored for 12 weeks. The goal is to …

This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) for people with ultra high-risk multiple myeloma that didn't respond well to first treatments. About 20 adults aged 18-65 will receive this one-two punch to see if it's safe and helps control…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people newly diagnosed with a rare type of spleen lymphoma called SBLPN. The goal is to see how well the treatment shrinks or controls the cancer and to check for side effects. About 4…

This study tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia (Ph-negative B-cell acute lymphoblastic leukemia). The goal is to see if this gentler approach can help more patients achieve a deep remis…

This study tests a new treatment for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a fast-growing blood cancer. It combines low-intensity chemotherapy with targeted drugs (venetoclax, blinatumomab, and olverembatinib) to impr…

This study tests whether adding rituximab to the standard drug eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) who have not responded to or relapsed after previous treatments. About 224 participants will receive either the combination…

This study compares two medications, daratumumab and rituximab, in children aged 6 to 17 with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to see w…

This study tests a new treatment called BCMA-CART, with or without a stem cell transplant, in young adults (18-55) newly diagnosed with multiple myeloma. The goal is to see if it can make the cancer disappear (MRD negative) and keep it away longer. About 50 people will join this …

This early-stage study tests a universal CAR T-cell therapy designed to target and destroy certain immune cells (those with CD19 or BCMA markers) that drive autoimmune diseases. It enrolls 12 adults with severe conditions like lupus, scleroderma, or vasculitis that have not respo…

This study tests a new treatment for children and teens with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a combination of targeted drugs (olverembatinib, blinatumomab, and venetoclax) can work as well as or better than sta…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people with untreated follicular lymphoma, a type of blood cancer. The goal is to see how well the treatment shrinks or controls the cancer. About 34 adults with stage II bulky or stag…

This early-phase study tests a personalized cell therapy (CD19 CAR-T) in 15 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cel…

This study tests whether a drug called chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either receive chidamide or be observed. The goal is to see…

This study tests a drug called golidocitnib in people with certain slow-growing but incurable blood cancers (T/NK-cell lymphomas) that have not responded to standard treatment. About 48 adults will receive the drug to see if it shrinks tumors and how safe it is. The goal is to co…

This study is for adults with a specific, high-risk type of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding targeted drugs (olverembatinib or gecacitinib) and venetoclax to standard chemotherapy can help more patients achieve a deep remissi…

This study tests a new treatment called supCD7 CART cells for people with certain blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia) that have come back or not responded to standard therapy. The cells are designed to find and attack cancer cells that carry a prote…

This study tests a drug called orelabrutinib in 30 people with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see how well the drug shrinks tumors and to check for side effects. Participants take the drug by mouth and are followed for response and s…

This early-phase study tests whether a person's own modified immune cells (CAR-T cells) can help control HIV without daily medication. Only 3 participants with well-controlled HIV will receive the treatment to check safety and see if the virus stays undetectable. The goal is a 'f…

This study tests whether a dietary supplement called sulforaphane (found in broccoli) can safely help blood cell recovery in adults receiving a cord blood transplant for blood cancers like leukemia or MDS. The cord blood used has been frozen for 10 years or more, which can damage…

This study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) who did not improve or relapsed after steroid treatment. The goal is to safely raise platelet counts and reduce ble…

This study tests a new drug called CM336, a bispecific antibody, in 21 people newly diagnosed with a rare disease called AL amyloidosis. The goal is to see if the drug can improve blood markers of the disease and to check for side effects. Participants will receive the drug and b…

This early study tests a new treatment called CD5CART for people with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells that carry a protein called CD5. The mai…

This study tests whether adding the targeted drug venetoclax to standard intensive chemotherapy improves outcomes for adults with acute myeloid leukemia (AML). The goal is to find out which genetic subtypes of AML respond best to this combination. About 380 participants aged 14 t…

This study tests whether a mobile app can help children with acute lymphoblastic leukemia keep their blood counts in a target range during maintenance therapy. About 100 children who have already shown good app use will be randomly assigned to continue with the app or not. The go…

This early-phase study tests a new type of cell therapy (CAR19-BCMA CAR-T) for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The main goal is to ch…

This study tests whether adding CAR-T cell therapy after standard chemotherapy can help adults newly diagnosed with a type of leukemia (Ph-negative B-ALL) achieve deeper remission and live longer. About 77 participants will receive the combination treatment. The goal is to reduce…

This study tests a new drug (anti-CD38 antibody) in 60 children aged 6 and older with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The drug aims to raise platelet counts safely in kids who haven't improved with standard …

This study tests a clotting medicine called prothrombin complex concentrate (PCC) to stop bleeding in people with hemophilia A who have developed inhibitors (antibodies that block standard treatment). About 30 participants aged 12 to 65 will receive PCC on-demand during bleeding …

This early-stage study tests whether adding methylene blue to standard care can safely reduce cytokine release syndrome (CRS) and neurotoxicity (ICANS) in 18 adults who developed these side effects after CAR-T or bispecific antibody treatment. Participants receive methylene blue …

This study uses a non-invasive brain imaging technique called fNIRS to see how anemia affects brain networks involved in thinking and memory. Researchers will monitor brain activity in 323 adults with anemia to identify which brain regions are impacted. The goal is to detect cogn…

This study is a registry that will follow about 100 adults and teens with hemophilia who are already taking marstacimab, a monthly shot under the skin. The main goal is to learn how patients feel about this treatment compared to the standard IV infusions, and to measure how much …

This study follows 500 children aged 6-17 diagnosed with immune thrombocytopenia (ITP), a rare condition where the immune system destroys platelets, causing bruising and bleeding. Researchers will track their symptoms, treatments, and outcomes over time to build a clearer picture…

This study looks at how well a medicine called L-AmB works for treating fungal infections in children and teens with blood cancers who are already taking other antifungal drugs. The goal is to see if it works as well in kids as it does in adults and if it causes fewer kidney prob…

This study looks at whether tests of the autonomic nervous system (which controls things like heart rate and goosebumps) can help predict a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. About 60 patients will have nerve function tests …

This study watches 200 people with aplastic anemia who are getting ATG/ALG therapy for the first time. Researchers will track side effects like serum sickness, organ damage, and infusion reactions to create better management guidelines. The goal is to make treatment safer and mor…

This study is creating a large database of people with various blood diseases in China, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, out…

This study looks at growth and health problems in children and teens with thalassemia, a blood disorder. Researchers will check physical development, hormones, nutrition, and brain function. They will then provide personalized care plans including monitoring, education, diet, and…

This study aims to learn about the health of elderly people, whether they live in nursing homes or at home. Researchers will track chronic diseases, cancers, and other health issues in 1,500 volunteers aged 60 and older. No treatments or medications are given—just observation and…